Abstract:Antibody-drug conjugates (ADCs) are a class of antineoplastic agents whose structure is composed of three main components: a monoclonal antibody (mAB) targeting a specific target antigen, a cytotoxic payload, and a linker binding the antibody to the payload. By combining the specificity of mABs with the high potency of the payloads, ADCs constitute a smart drug delivery system with improved therapeutic index. After recognition and binding of the mAB to its target surface antigen, ADCs are internalized by endocytosis by the tumor cell, releasing the payloads into the cytoplasm, where they exert their cytotoxic activity, eventually leading to cell death. The composition of some of the new ADCs confers additional functional properties that allow expanding their activity to neighboring cells not expressing the target antigen, constituting a valuable strategy to overcome tumor heterogeneity. Some of these 'off-target effects', such as the bystander effect, are possibly the mechanism underlying the antitumor activity demonstrated in patients with low expression of the target antigens, which represents an important paradigm shift in anticancer targeted therapy. Three ADCs are currently approved for the treatment of breast cancer (BC); two anti-HER2 (human epidermal growth factor receptor 2) ADCs (trastuzumab emtansine and trastuzumab deruxtecan); and one Trop-2-targeted ADC (sacituzumab govitecan). Based on the unprecedented efficacy data demonstrated by these agents, ADCs have been incorporated as part of standard regimens for all subtypes of advanced BC, as well as for high-risk early HER2-positive BC. Despite the remarkable advances, several hurdles still remain to overcome, including the development of reliable biomarkers for patient selection, prevention, and management of potentially severe toxicities, ADC resistance mechanisms, post-ADC resistance patterns, and optimal treatment sequencing and combinations. In this review, we will summarize the currently available evidence related to the use of these agents, as well as explore the current landscape of ADC development for BC treatment.

Role of CIS in Replication of an IncB Plasmid

Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes

Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design

A Review of Current and Future Antibody Drug Conjugates in Breast Cancer

New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development

Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment

Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer

Recent advances in antibody-drug conjugates for breast cancer treatment.

Head injuries in a general surgical unit.

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

Targeting cancer with antibody-drug conjugates: Promises and challenges

[Antibody-Drug Conjugates in Breast Cancer and Gynecologic Cancer]

Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate

Decreased insulin response in dairy cows following a four-day fast to induce hepatic lipidosis.

Diffusion-tensor magnetic resonance imaging detects normal-appearing white matter damage unrelated to short-term disease activity in patients at the earliest clinical stage of multiple sclerosis.

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

Breast Cancer Treatment and Antibody Drug Conjugates: Beyond T-DM1

Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions

Antibody–drug conjugates transform the outcome of individuals with low‐HER2‐expression advanced breast cancer

Antibody-drug conjugates: Principles and opportunities

Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions